May 9, 2025 02:31 PM EDT

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Nicole DeFeudis

Editor

Iovance Biotherapeutics’ stock $IOVA dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales predictions and reported lower-than-expected sales …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

Nicole DeFeudis

Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Revolution’s KRAS drugs appear competitive in several lung cancer settings

Chronic care startup Omada Health files to go public

Corvus' early-phase atopic dermatitis data prompt stock rally

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi